HUP0600335A2 - Human antibodies that have mn binding and cell adhesion-neutralizing activity - Google Patents

Human antibodies that have mn binding and cell adhesion-neutralizing activity

Info

Publication number: HUP0600335A2
Authority: HU; Hungary
Prior art keywords: binding; human antibodies; cell adhesion; neutralizing activity; neutralizing
Prior art date: 2001-10-18

Application number

HU0600335A

Other languages

English (en)

Inventor

Toshihiko Takeuchi

Nathalie Dubois-Stringfellow

John E Murphy

Julie Rinkenberger

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-18

Filing date

2002-10-18

Publication date

2006-08-28

2002-10-18 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2006-08-28 Publication of HUP0600335A2 publication Critical patent/HUP0600335A2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

HU0600335A 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity HUP0600335A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US34365701P	2001-10-18	2001-10-18
US37771602P	2002-05-02	2002-05-02
PCT/US2002/033470 WO2003033674A2 (en)	2001-10-18	2002-10-18	Human antibodies that have mn binding and cell adhesion-neutralizing activity

Publications (1)

Publication Number	Publication Date
HUP0600335A2 true HUP0600335A2 (en)	2006-08-28

Family

ID=26993561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0600335A HUP0600335A2 (en)	2001-10-18	2002-10-18	Human antibodies that have mn binding and cell adhesion-neutralizing activity

Country Status (18)

Country	Link
US (2)	US7462696B2 (hu)
EP (1)	EP1438339A4 (hu)
JP (2)	JP2005528884A (hu)
KR (1)	KR20050037478A (hu)
CN (1)	CN1606569A (hu)
AR (1)	AR036833A1 (hu)
BR (1)	BR0213968A (hu)
CA (1)	CA2463943A1 (hu)
CO (1)	CO5370684A1 (hu)
DO (1)	DOP2002000494A (hu)
HU (1)	HUP0600335A2 (hu)
IL (1)	IL161411A0 (hu)
MX (1)	MXPA04003508A (hu)
PE (1)	PE20030473A1 (hu)
PL (1)	PL374304A1 (hu)
RU (1)	RU2317998C2 (hu)
UY (1)	UY27499A1 (hu)
WO (1)	WO2003033674A2 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040191246A1 (en) *	2003-02-26	2004-09-30	Connelly Patrick R.	Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US20090162382A1 (en) *	2002-03-01	2009-06-25	Bernett Matthew J	Optimized ca9 antibodies and methods of using the same
US7504364B2 (en)	2002-03-01	2009-03-17	Receptors Llc	Methods of making arrays and artificial receptors
WO2005003326A2 (en)	2003-03-28	2005-01-13	Receptors Llc.	Artificial receptors including reversibly immobilized building blocks and methods
US7469076B2 (en)	2003-09-03	2008-12-23	Receptors Llc	Sensors employing combinatorial artificial receptors
EP1664778A2 (en) *	2003-09-03	2006-06-07	Receptors LLC	Nanodevices employing combinatorial artificial receptors
WO2006028930A2 (en)	2004-09-03	2006-03-16	Receptors Llc	Combinatorial artificial receptors including tether building blocks on scaffolds
WO2006029383A2 (en)	2004-09-11	2006-03-16	Receptors Llc	Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) *	2007-04-12	2014-09-18	Universiteit Hasselt	Biomarkers for multiple sclerosis
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2726345C (en) *	2008-05-30	2018-08-28	John Simard	Interleukin-1 alpha antibodies and methods of use
EP2766048B1 (en)	2012-10-12	2014-12-10	Spirogen Sàrl	Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en)	2013-03-13	2016-02-04	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
EP3126837B1 (en) *	2014-04-03	2021-09-15	AllerGenis, LLC	Peptides and methods for detecting food allergy
US10188746B2 (en)	2014-09-10	2019-01-29	Medimmune Limited	Pyrrolobenzodiazepines and conjugates thereof
US20200023072A1 (en)	2016-10-11	2020-01-23	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
BR112020023846A2 (pt)	2018-05-23	2021-04-13	Adc Therapeutics Sa	Adjuvante molecular
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
EP4426727A2 (en)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
EP0710719B1 (en) *	1990-01-12	2007-03-14	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US6297051B1 (en) *	1997-01-24	2001-10-02	Institute Of Virology, Slovak Academy Of Sciences	MN gene and protein
AU2861695A (en) *	1994-06-15	1996-01-05	Ciba Corning Diagnostics Corp.	Mn gene and protein
EP1832653A1 (en) *	1998-10-23	2007-09-12	Institute Of Virology	MN gene and protein
US6689744B2 (en) *	2000-09-22	2004-02-10	Genentech, Inc.	Notch receptor agonists and uses

2002
- 2002-10-16 AR ARP020103877A patent/AR036833A1/es unknown
- 2002-10-17 DO DO2002000494A patent/DOP2002000494A/es unknown
- 2002-10-17 UY UY27499A patent/UY27499A1/es not_active Application Discontinuation
- 2002-10-18 EP EP02786449A patent/EP1438339A4/en not_active Withdrawn
- 2002-10-18 PL PL02374304A patent/PL374304A1/xx not_active Application Discontinuation
- 2002-10-18 BR BR0213968-5A patent/BR0213968A/pt not_active IP Right Cessation
- 2002-10-18 JP JP2003536404A patent/JP2005528884A/ja active Pending
- 2002-10-18 KR KR1020047005716A patent/KR20050037478A/ko not_active Withdrawn
- 2002-10-18 PE PE2002001031A patent/PE20030473A1/es not_active Application Discontinuation
- 2002-10-18 WO PCT/US2002/033470 patent/WO2003033674A2/en active Application Filing
- 2002-10-18 CO CO02094163A patent/CO5370684A1/es unknown
- 2002-10-18 CN CNA028254880A patent/CN1606569A/zh active Pending
- 2002-10-18 MX MXPA04003508A patent/MXPA04003508A/es not_active Application Discontinuation
- 2002-10-18 CA CA002463943A patent/CA2463943A1/en not_active Abandoned
- 2002-10-18 RU RU2004115112/13A patent/RU2317998C2/ru not_active IP Right Cessation
- 2002-10-18 IL IL16141102A patent/IL161411A0/xx unknown
- 2002-10-18 US US10/273,541 patent/US7462696B2/en not_active Expired - Fee Related
- 2002-10-18 HU HU0600335A patent/HUP0600335A2/hu unknown
2008
- 2008-12-08 US US12/330,504 patent/US20100240100A1/en not_active Abandoned
2010
- 2010-02-01 JP JP2010020670A patent/JP2010260845A/ja active Pending

Also Published As

Publication number	Publication date
US20100240100A1 (en)	2010-09-23
WO2003033674A2 (en)	2003-04-24
IL161411A0 (en)	2004-09-27
EP1438339A4 (en)	2008-08-27
UY27499A1 (es)	2003-05-30
US7462696B2 (en)	2008-12-09
CA2463943A1 (en)	2003-04-24
AR036833A1 (es)	2004-10-06
US20030077277A1 (en)	2003-04-24
PL374304A1 (en)	2005-10-03
CO5370684A1 (es)	2004-02-27
JP2005528884A (ja)	2005-09-29
RU2004115112A (ru)	2005-04-27
WO2003033674A3 (en)	2003-08-21
KR20050037478A (ko)	2005-04-22
PE20030473A1 (es)	2003-06-26
EP1438339A2 (en)	2004-07-21
DOP2002000494A (es)	2004-05-31
BR0213968A (pt)	2005-05-10
MXPA04003508A (es)	2004-07-22
JP2010260845A (ja)	2010-11-18
CN1606569A (zh)	2005-04-13
RU2317998C2 (ru)	2008-02-27

Publication	Publication Date	Title
HUP0600335A2 (en)	2006-08-28	Human antibodies that have mn binding and cell adhesion-neutralizing activity
IL225633A0 (en)	2014-03-31	Antibodies against alpha v beta 6 and uses thereof
EP1353941A4 (en)	2005-12-21	PROT INES OF FINGER LINK OF MODIFIED GLOVE ES
EP1551447A4 (en)	2007-03-07	ANTI-ADDL ANTIBODIES AND USES THEREOF
ZA200206266B (en)	2003-11-06	Antibodies that bind human interleukin-18 and methods of making and using.
AU2001298042A8 (en)	2005-11-03	Optimized pulsatile-flow ventricular-assist device and total artificial heart
PT2368907T (pt)	2016-09-20	Anticorpos anti-abeta e a sua utilização
IL201751A (en)	2013-06-27	Compounds that bind il-17-like cytokine and antibodies
IL206832A0 (en)	2010-12-30	Antibodies binding an 161p2f10b epitope and uses thereof
AU2001256325A1 (en)	2001-09-24	Human and humanized fap-alpha-specific antibodies
AU7676300A (en)	2001-04-23	Human anti-adipocyte monoclonal antibodies and their use
HUP0400697A3 (en)	2007-05-02	Silensed anti-cd28 antibodies and use thereof
AU2003296369A8 (en)	2004-06-30	Imminoamines and preparation thereof
EP1436233A4 (en)	2006-03-29	BINDING PROTEINS WITH METALS AND RELATED METHODS
AU2003219093A8 (en)	2003-10-08	Anti-hpv-16 e7 antibodies and their use
GB9928950D0 (en)	2000-02-02	Binding protein
IL166063A0 (en)	2006-01-15	Antibodies and uses thereof
GB0102717D0 (en)	2001-03-21	Cells and uses therefor
GB0217548D0 (en)	2002-09-11	Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
IL149851A0 (en)	2002-11-10	Resistin binding proteins, their preparation and use
IL151980A0 (en)	2003-04-10	Resistin binding proteins, their preparation and use
EP1044212A4 (en)	2004-11-24	FK506 HUMAN BINDING PROTEINS
GB0200843D0 (en)	2002-03-06	Benzodioxinopyrroles their preparation and use
HK1072538A1 (en)	2005-09-02	Immunoregulatory antibodies and uses thereof
IL142187A0 (en)	2002-03-10	Resistin binding proteins, their preparation and use

Legal Events

Date	Code	Title	Description
2007-05-29	FD9A	Lapse of provisional protection due to non-payment of fees